Chrystal U. Louis

6.6k total citations · 4 hit papers
56 papers, 4.6k citations indexed

About

Chrystal U. Louis is a scholar working on Oncology, Neurology and Immunology. According to data from OpenAlex, Chrystal U. Louis has authored 56 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 16 papers in Neurology and 13 papers in Immunology. Recurrent topics in Chrystal U. Louis's work include CAR-T cell therapy research (18 papers), Neuroblastoma Research and Treatments (16 papers) and Virus-based gene therapy research (10 papers). Chrystal U. Louis is often cited by papers focused on CAR-T cell therapy research (18 papers), Neuroblastoma Research and Treatments (16 papers) and Virus-based gene therapy research (10 papers). Chrystal U. Louis collaborates with scholars based in United States, Italy and France. Chrystal U. Louis's co-authors include Nabil Ahmed, Michael C. Jensen, Stephan A. Grupp, David Porter, Daniel W. Lee, Crystal L. Mackall, Rebecca Gardner, Jason M. Shohet, Helen E. Heslop and Cliona M. Rooney and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Chrystal U. Louis

52 papers receiving 4.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Current concepts in the diagnosis and management of cytokine release syndrome

2014 1.9k citations Chrystal U. Louis, Nabil Ahmed et al. Blood profile →
Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma

2011 882 citations Chrystal U. Louis, Barbara Savoldo et al. Blood profile →
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma

2017 391 citations Andras Heczey, Chrystal U. Louis et al. Molecular Therapy profile →
Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma

2025 14 citations Sandhya Sharma, Andras Heczey et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chrystal U. Louis United States	20	3.5k	1.3k	1.1k	1.1k	819	56	4.6k
Daniel W. Lee United States	26	3.4k 1.0×	937 0.7×	1.0k 0.9×	971 0.9×	302 0.4×	60	4.7k
Bianca Santomasso United States	19	3.2k 0.9×	764 0.6×	779 0.7×	683 0.6×	201 0.2×	46	3.7k
Frederick L. Locke United States	34	5.2k 1.5×	1.4k 1.0×	1.4k 1.3×	1.2k 1.1×	233 0.3×	307	6.0k
Craig S. Sauter United States	29	3.4k 1.0×	973 0.7×	777 0.7×	830 0.8×	573 0.7×	189	4.7k
Jennifer N. Brudno United States	19	2.9k 0.8×	928 0.7×	1.0k 0.9×	730 0.7×	140 0.2×	28	3.5k
Shannon L. Maude United States	33	7.7k 2.2×	2.5k 2.0×	2.1k 1.9×	2.2k 2.0×	377 0.5×	107	9.2k
Matthew A. Lunning United States	29	2.0k 0.6×	700 0.5×	679 0.6×	281 0.3×	257 0.3×	163	3.4k
Nirav N. Shah United States	28	1.7k 0.5×	615 0.5×	823 0.7×	390 0.4×	130 0.2×	207	3.1k
Shaun O’Brien United States	22	2.6k 0.8×	2.1k 1.6×	1.5k 1.3×	399 0.4×	72 0.1×	44	4.9k
Susanna Harju-Baker United States	13	1.6k 0.5×	398 0.3×	432 0.4×	420 0.4×	120 0.1×	19	2.1k

Countries citing papers authored by Chrystal U. Louis

Since Specialization

Citations

This map shows the geographic impact of Chrystal U. Louis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chrystal U. Louis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chrystal U. Louis more than expected).

Fields of papers citing papers by Chrystal U. Louis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chrystal U. Louis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chrystal U. Louis. The network helps show where Chrystal U. Louis may publish in the future.

Co-authorship network of co-authors of Chrystal U. Louis

This figure shows the co-authorship network connecting the top 25 collaborators of Chrystal U. Louis. A scholar is included among the top collaborators of Chrystal U. Louis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chrystal U. Louis. Chrystal U. Louis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Malki, Monzr M. Al, Alla Keyzner, Yibin Chen, et al.. (2025). TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial (NCT05473910). Transplantation and Cellular Therapy. 31(2). S59–S60.

Sharma, Sandhya, Andras Heczey, Mae Woods, et al.. (2025). Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma. Nature Medicine. 31(4). 1125–1129. 14 indexed citations breakdown →

Marón, Gabriela, Allistair Abraham, Alice Bertaina, et al.. (2024). Strategic infection prevention after genetically modified hematopoietic stem cell therapies: recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee. Cytotherapy. 26(7). 660–671. 4 indexed citations

Gupta, Ashish O., Senthil Velan Bhoopalan, Allistair Abraham, et al.. (2024). International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the current state of hematopoietic stem and progenitor cell–based genomic therapies and the challenges faced. Cytotherapy. 26(11). 1411–1420. 4 indexed citations

Abraham, Allistair, Alice Bertaina, Senthil Velan Bhoopalan, et al.. (2023). International Society for Cell & Gene Therapy Stem Cell Engineering Committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant. Cytotherapy. 25(6). 578–589. 2 indexed citations

Goldman, Jonathan W., David Waterhouse, Ben George, et al.. (2019). Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer. Frontiers in Oncology. 9. 1256–1256. 12 indexed citations

Wainberg, Zev A., Howard S. Höchster, Edward Kim, et al.. (2019). Phase I study of nivolumab (Nivo) + nab-paclitaxel (nab-P) + gemcitabine (Gem) in advanced pancreatic cancer (APC).. Journal of Clinical Oncology. 37(4_suppl). 298–298. 27 indexed citations

Sahai, Vaibhav, Aparna Kalyan, Philip A. Philip, et al.. (2019). A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab -Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer. SHILAP Revista de lepidopterología. 5(1). 35–42. 11 indexed citations

Pace, Emily A., Sharlene Adams, Michael D. Curley, et al.. (2018). Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. Clinical Cancer Research. 24(12). 2873–2885. 44 indexed citations

10.

Picozzi, Vincent J., Vaibhav Sahai, Diane M. Simeone, et al.. (2017). A phase 1/2 study of metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer. Annals of Oncology. 28. iii81–iii82. 1 indexed citations

11.

Heczey, Andras, Chrystal U. Louis, Barbara Savoldo, et al.. (2017). CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Molecular Therapy. 25(9). 2214–2224. 391 indexed citations breakdown →

12.

Goldstein, David, Daniel D. Von Hoff, Elena G. Chiorean, et al.. (2017). Relative contribution of baseline variables in a nomogram to predict survival in patients treated with nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer. Annals of Oncology. 28. iii142–iii144.

13.

Hegde, Meenakshi, et al.. (2014). Cellular immunotherapy for pediatric solid tumors. Cytotherapy. 17(1). 3–17. 13 indexed citations

14.

Louis, Chrystal U., Karin Straathof, Catherine M. Bollard, et al.. (2010). Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma. Journal of Immunotherapy. 33(9). 983–990. 160 indexed citations

15.

Cruz, Carolina Colli, Patrick J. Hanley, Hao Liu, et al.. (2010). Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy. 12(6). 743–749. 60 indexed citations

16.

Ahmed, Nabil, Vita S. Salsman, Eric Yvon, et al.. (2009). Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression. Molecular Therapy. 17(10). 1779–1787. 167 indexed citations

17.

Louis, Chrystal U. & M.K. Brenner. (2009). Cellular Immunotherapy for Neuroblastoma: A Review of Current Vaccine and Adoptive T Cell Therapeutics. Current Pharmaceutical Design. 15(4). 424–429. 13 indexed citations

18.

Cruz, Carolina Colli, Patrick J. Hanley, Hao Liu, et al.. (2009). Adverse Events Following Infusion of T Cells for Adoptive Immunotherapy: A 10 Year Experience.. Blood. 114(22). 3212–3212. 1 indexed citations

19.

Louis, Chrystal U., Karin Straathof, Claudia Gerken, et al.. (2008). 244: Treatment of Epstein Barr Virus Positive Nasopharyngeal Carcinoma with Adoptively Transferred Cytotoxic T Lymphocytes. Biology of Blood and Marrow Transplantation. 14(2). 90–90. 1 indexed citations

20.

Gottschalk, Stephen, Catherine M. Bollard, Karin Straathof, et al.. (2007). T Cell Therapies. PubMed. 69–82. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact